氘可来昔替尼价格一览

Introduction: Deuterated colexitinib was successfully approved for the first time in the United States in September 2022 for the treatment of plaque psoriasis. There is a significant price difference between its original drug and generic drugs. This article will conduct a detailed analysis from three aspects: the price of the original and generic drugs of deuterated colexitinib, medical insurance reimbursement policies, and precautions for use, to help patients better understand the economics and usage specifications of this drug.

Prices of the original drug and generic drug of Deuterocolexitinib

There is a big difference in price between the original drug and the generic drug, mainly due to differences in research and development costs, production processes and market positioning. Understanding these differences will help patients choose the right drug according to their own economic situation. The price is for reference only, and patients need to refer to the actual price.

Original drug price

The original drug of deuterated colexitinib has been launched in China and is included in medical insurance and enjoys medical insurance reimbursement. The winning bid price of medical insurance is approximately US$137 and US$204. The specific price after reimbursement will be lower and needs to be calculated according to the reimbursement ratio of each region.

Price of generic drugs

Generic drugs are produced after the patent of the original drug expires, and the price is relatively low. The generic version of deuterated colexitinib produced by Ziska Pharmaceutical Factory in Bangladesh is 6mg*30 pills per box, and the price per box is approximately US$82.

When patients choose deuterated colexitinib, they can choose between the original drug and generic drugs based on their own financial conditions and doctor's advice.

Reimbursement of deuterated colexitinib by medical insurance

The medical insurance reimbursement policy is an important factor affecting the cost of deuterated colexitinib. Medical insurance policies vary in different regions, and patients need to understand the specific local reimbursement situation.

Medical insurance coverage

In some areas, deuterated colexitinib has been included in the medical insurance reimbursement catalog. Patients can reimburse part of the expenses through medical insurance. The specific reimbursement ratio and limit need to be determined according to local medical insurance policies. Usually the reimbursement ratio is between 50% and 70%.

Reimbursement process

When patients use deuterated colexitinib, they must first receive a prescription from a doctor and purchase the drug at a medical insurance designated hospital or pharmacy. After purchasing, patients can go to the medical insurance department to handle reimbursement procedures with relevant receipts and medical insurance cards.

Calculation of out-of-pocket expenses

Even if included in medical insurance, patients still need to bear part of their out-of-pocket expenses. The out-of-pocket portion is calculated as the total drug cost minus the medical insurance reimbursement amount. Patients should know the amount of out-of-pocket expenses in advance and make financial preparations.

The medical insurance reimbursement policy provides important financial support to patients, and rational use of medical insurance resources can significantly reduce treatment costs.

Precautions for deuterated colexitinib

When using deuterated colexitinib, patients need to pay attention to some key matters.

Contraindications

Deuterated colexitinib is not suitable for all patients. People who are allergic to the drug ingredients, pregnant women and lactating women should avoid its use. Patients must inform their doctor in detail about their health status and medication history before use.

Drug Interactions

Deuterated colexitinib may interact with other drugs, affecting drug efficacy or increasing the risk of adverse reactions. When patients are taking other drugs, they need to consult their doctor whether it is suitable to use them at the same time as colexitinib.

Adverse reaction monitoring

Deuterated colexitinib may cause some adverse reactions, such as headache, nausea, fatigue, etc. Patients should closely observe their physical reactions during medication. If serious discomfort occurs, they need to seek medical treatment in time.

By paying attention to the above matters, patients can better use deuterated coxitinib to ensure treatment effects and reduce potential risks.